Outlook Therapeutics, Inc.
OTLK
$2.70
-$0.27-9.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 21.23% | -33.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 39.24% | -42.65% | |||
| Operating Income | -27.09% | 42.65% | |||
| Income Before Tax | 56.53% | -366.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 56.53% | -366.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 56.53% | -366.76% | |||
| EBIT | -27.09% | 42.65% | |||
| EBITDA | -27.15% | 42.71% | |||
| EPS Basic | 63.68% | -309.39% | |||
| Normalized Basic EPS | 67.83% | -294.54% | |||
| EPS Diluted | 63.37% | -309.39% | |||
| Normalized Diluted EPS | 67.83% | -294.54% | |||
| Average Basic Shares Outstanding | 19.70% | 27.40% | |||
| Average Diluted Shares Outstanding | 19.70% | 27.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||